What is ASMB's current stock price?

ASMB (Assembly Biosciences, Inc.) is currently trading at $28.34 with a market cap of $450.4M.

What sector is Assembly Biosciences, Inc. in?

Assembly Biosciences, Inc. (ASMB) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is ASMB a good stock to buy?

Analysts have a Buy consensus on ASMB with a price target of $37.67. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

ASMB Assembly Biosciences, Inc.

Healthcare

$28.34+6.94%ClosedMarket Cap: $450.4M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.41

P/S

6.33

EV/EBITDA

-35.85

DCF Value

$-65.18

FCF Yield

-8.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

77.2%

Operating Margin

-19.1%

Net Margin

-9.0%

ROE

-4.2%

ROA

-2.7%

ROIC

-6.7%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$8.2M	$-9.1M	$—
Q4 null	$42.5M	$22.1M	$—
FY null	$72.3M	$-6.1M	$—
Q3 null	$10.8M	$-9.2M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$37.67

Target (Median)

$38.00

Target Range

$35.00 - $40.00

0 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-05-04

GuggenheimBuy

2026-04-06

HC Wainwright & Co.Buy

2026-03-26

HC Wainwright & Co.Buy

2025-12-22

MizuhoOutperform

2025-11-20

Trading Activity

Insider Trades

View All

White Nicole Sofficer: Chief Manufacturing Officer

SellTue Mar 31

White Nicole Sofficer: Chief Manufacturing Officer

SellTue Mar 31

White Nicole Sofficer: Chief Manufacturing Officer

SellTue Mar 31

Okazaki Jason Adirector, officer: CEO and President

SellTue Mar 31

Gaggar Anujofficer: Chief Medical Officer

SellTue Mar 31

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.09

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Peers